Details of the Drug

General Information of Drug (ID: DMXZ84M)

• Drug Name: Malathion
• Synonyms: Calmathion; Camathion; Carbafos; Carbetovur; Carbetox; Carbofos; Carbophos; Celthion; Chemathion; Cimexan; Cleensheen; Cythion; Dorthion; Emmatos; Ethiolacar; Etiol; Extermathion; Flair; Forthion; Fosfothion; Fosfotion; Fyfanon; Hilthion; Karbofos; Kypfos; Malacide; Malafor; Malagran; Malakill; Malamar; Malaphele; Malaphos; Malasol; Malaspray; Malataf; Malathiazol; Malathione; Malathiozoo; Malathon; Malathyl; Malation; Malatol; Malatox; Maldison; Malmed; Malphos; Maltox; Mercaptothion; Mercaptotion; Moscarda; Oleophosphothion; Organoderm; Ovide; Paladin; Phosphothion; Prioderm; Sadofos; Sadophos; Sumitox; TAK; Taskil; Vetiol; Zithiol; Carbethoxy malathion; Detm ol ma; Detmol MA; Emmatos extra; Lice Rid;Malathion LV Concentrate; Malathion [USP]; Malation [Polish]; Maltox MLT; Mercaptosuccinic acid diethyl ester; Mercaptotion [Spanish]; Ortho Malathion; Siptox I; Vegfru malatox; AC 26691; EL 4049; Experimental insecticide 4049; Fog 3; Fosfotion 550; Hilthion 25wdp; IFO 13140; Latka 4049; Latka 4049 [Czech]; MET86C_SUPELCO; Malamar 50; Malathion 60; Malathion E50; OMS 1; PS86_SUPELCO; SF 60; Sadofos 30; American cyanamid 4,049; Derbac-M; ENT 17,034; Four thousand forty-nine; Insecticide no. 4049; Kop-Thionkypfosmalacide; Kop-thion; Malathion (USP); Malathion (old ID); Ovide (TN); Staeubol-Puder; Suleo-M; TM-4049; Kill-A-Mite; MALATHION, 96%; Malathion-2,3-14C; 8059HC

Indication

Disease Entry	ICD 11	Status	REF
Pediculus capitis infestation	1G00.0	Approved	[1]

• Therapeutic Class: Parasympathomimetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 330.4
  Topological Polar Surface Area (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 24 hours [2]
  Metabolism: The drug is metabolized via the carboxyesterases [3]
• Chemical Identifiers:
  Formula: C10H19O6PS2
  IUPAC Name: diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate
  Canonical SMILES: CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC
  InChI: InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3
  InChIKey: JXSJBGJIGXNWCI-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4004
  ChEBI ID: CHEBI:6651
  CAS Number: 121-75-5
  DrugBank ID: DB00772
  TTD ID: D0K3LW
  INTEDE ID: DR1000
  ACDINA ID: D01234

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[5]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Pediculus capitis infestation
• ICD Disease Classification: 1G00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Acetylcholinesterase (AChE)	DTT	ACHE	6.39E-02	-1.07	-1.15
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Alpha-terpineol	E00250	17100	Antioxidant; Flavoring agent; Solvent
Limonene	E00705	22311	Flavoring agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Malathion 0.5% lotion	0.50%	Lotion	Topical

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 078743.
• [2] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [3] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [4] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [5] Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
• [6] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [7] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [8] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [9] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [10] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [11] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [12] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [13] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [14] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [15] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [16] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [17] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [18] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [19] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [20] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [21] Drugs that may have potential CYP2B6 interactions.
• [22] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [23] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [24] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [25] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [26] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [28] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [29] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [30] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [31] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [32] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [33] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [34] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [35] Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.